Manufacturing

Over the past 25 years, the dynamics of business relationships between Contract Development and Manufacturing Organizations (CDMOs) and drug developers have transformed considerably, primarily driven by the expansion of CDMO capabilities and expertise.

The CDMO outsourcing market initially focused on addressing supply chain inefficiencies, enabling drug developers to manage fixed costs and mitigate capacity fluctuations. As CDMOs have grown and evolved, drug developers have begun to rely on these organizations for access to specific technologies, skills, and scientific expertise that are lacking in-house. ISR’s contract manufacturing market research dives deep into the CDMO outsourcing market, providing valuable insights to help drug innovators navigate the dynamic landscape of drug manufacturing. We aim to empower drug developers to identify the most suitable outsourcing model that aligns with their organizational needs and to make informed decisions about CDMO selection based on robust data gathered from outsourcing peers.

Moreover, CDMOs also stand to benefit from gaining a thorough understanding of the competitive landscape within the CDMO outsourcing market via our research, which includes key drivers of outsourcing, selection criteria for CDMOs, and insight into the decision-making process. This knowledge will help service providers better meet the needs of drug developers in this continuously evolving market.